CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Investing.com - Xeris Pharmaceuticals reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Xeris Pharmaceuticals announced earnings per share of $-0.160 on revenue of $29.6M. Analysts polled by Investing.com EPS of $-0.190 on revenue of $30.29M.
Xeris Pharmaceuticals 's are down 16.73% and is trading at $1.570 , still down 50.93% from its 52 week high of $3.17 set on Friday, December 31, 2021.
Xeris Pharmaceuticals shares gained 0.96% to trade at $1.570 in pre-market trade the report.
Xeris Pharmaceuticals follows other major Healthcare sector earnings this month
Xeris Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar